See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that has been used to treat various bacterial infections, including those caused by Bacteroides fragilis, a type of bacteria that can cause severe intra-abdominal and other invasive infections [1]. However, whether tigecycline is a preferred choice over other antibiotics for B. fragilis infections is a complex question that depends on several factors.

Tigecycline has several potential advantages over other antibiotics for treating B. fragilis infections. It has a broad spectrum of activity, including against many drug-resistant bacteria, and it is not affected by many of the resistance mechanisms that limit the effectiveness of other antibiotics [1]. Additionally, tigecycline has good tissue penetration and distribution, making it a useful option for treating invasive infections [1].

However, tigecycline also has some limitations that may make it less preferable than other antibiotics for treating B. fragilis infections. For example, tigecycline has a higher rate of treatment-emergent Clostridioides difficile infection (CDI) than some other antibiotics, which can cause severe diarrhea and other complications [1]. Additionally, tigecycline has a higher rate of treatment failure than some other antibiotics for certain types of infections, such as complicated intra-abdominal infections [1].

Moreover, tigecycline is associated with a higher risk of mortality than some other antibiotics for certain types of infections, such as complicated skin and soft tissue infections and bacteremia [1]. The reason for this increased mortality risk is not fully understood but may be related to factors such as delayed bacterial clearance or adverse effects of the drug [1].

Therefore, while tigecycline may be a useful option for treating B. fragilis infections in certain situations, it is not always a preferred choice over other antibiotics. The choice of antibiotic for treating B. fragilis infections should be based on factors such as the severity and location of the infection, the susceptibility of the bacteria, the patient's medical history and other factors, and the potential risks and benefits of different antibiotics [1].

In summary, tigecycline can be an effective antibiotic for treating B. fragilis infections, but it is not always a preferred choice over other antibiotics. The decision to use tigecycline should be based on a careful evaluation of the patient's condition and the potential risks and benefits of different treatment options.

Sources:
[1] FDA. Tigecycline (marketed as Tygacil) prescribing information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s010lbl.pdf>